摘要
目的探讨摩根菌对抗菌药物的体外敏感性,为临床合理用药提供参考。方法对我院2002年1月到2005年6月临床分离的91株摩氏摩根菌的来源和药敏情况进行统计分析。结果多种临床标本中均可分离到摩根菌,其中较多来自痰液(37.4%)及分泌物标本(27.5%)。住院及门诊患者均可发生摩根菌感染,以老年科(15株,16.5%)、骨科(11株,12.1%)居多。所有摩氏摩根菌株对氨苄西林、头孢唑林、头孢噻吩均耐药,对氨苄西林/舒巴坦(77.8%)、头孢呋肟(87.2%)及复方磺胺甲唑(72.2%)耐药率也较高,而对哌拉西林/三唑巴坦、头孢吡肟、亚胺培南、阿米卡星的敏感性较好,敏感率分别为92.2%、85.7%、83.5%和94.5%。此外随年份增长摩根菌对各种抗生素的敏感性并无下降的趋势。结论在临床工作中应重视不常见致病菌引起的感染;哌拉西林/三唑巴坦、头孢吡肟、亚胺培南和阿米卡星等可作为临床治疗摩根菌感染的一线药物。
Objective To investigate the in vitro antimicrobial susceptibility of Morganella morganii and guide the rational use of drug clinically. Method We performed statistical analysis of the susceptibility of 91 strains of M. morganii isolated in our hospital from January 2002 to June 2005. Results M. morganii can be isolated from various specimens, most of them were isolated from sputum（37.4% ） and secretion（27.5% ）. Both hospitalized patients and out-patients can be infected, but more strains isolated from geratologous wards（15 strains, 16.5% ） and osseous wards （11 strains, 12. 1% ）. All isolates were resistant to ampicillin, cefazolin and cephalothin, and most were resistant to ampicillin/sulbactam （77. 8% ）, cefuroxime （87.2%） and trimethoprim/sulfamethoxazole （72. 2% ）, while , they were highly susceptible to piperacillin/tazobactam（92.2% ）, cefepime（85.7% ）, imipenem（83.5% ） and amikacin （94. 5% ）, and the resistance rates didn＇t change during the last 3 years. Conclusion Clinical infections caused by rare microorganisms should not be ignored, antibiotics such as piperacillin/tazobactam, cefepime, imipenem and amikacin are recommended as first-line therapy choices for the treatment of infections caused by M. morganii.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2006年第8期501-504,共4页
Chinese Journal of Antibiotics
关键词
摩氏摩根菌
药物敏感性
耐药
Morganella morganii
Antimicrobial susceptibility test
Resistance
